Retrospective Analysis of Spray Skin Treats for Severe Burns

Morality Clinical Trial

Official title:

A Real-world 10-year Single Center Experience With Spray Skin in the Treatment of Extensive Severe Burns

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06170424
• Other study ID #: SYSU-FAH-2019287
• Status: Completed
• Start date: January 1, 2012
• Est. completion date: December 31, 2022

Study information

• Verified date: December 2023
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study investigated the efficacy of novel approach spray skin for extensive severe burns treatment.

Description:

Burns are a global public health problem. This study investigated the efficacy of novel approach spray skin (autologous skin cell suspension combined with split-thickness skin grafting, STSG) for extensive severe burns treatment. We performed a real-world retrospective analysis of extensive burns patients (> 50% TBSA) from our hospital last 10 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients with > 50% TBSA

Exclusion Criteria:

• died within 1 week after admission
• admitted to hospital more than 1 week after injury

Related Conditions & MeSH terms

• Morality
• Skin Graft Complications

Intervention

Procedure:
• spray skin
The patients who used the autologous skin cell suspension combined with skin grafting.
• Control group
The patients who used skin grafting.

Locations

Country	Name	City	State
China	Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival rate	Patient survival during hospitalization	through study completion, an average of 1 year
Secondary	complication of skin graft	the survival of grafting skin	the take rate in the postoperative day 30, 60, 90
Secondary	length of hospital	The time during which the patient was hospitalized	through study completion, usually no more than 6 months